|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1987; 10:845-850 © 1987 by the American College of Cardiology Foundation |
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
Maximal oxygen uptake (VO2), skeletal muscle blood flow by xenon-133 washout technique and femoral vein arteriovenous oxygen difference and lactate were measured at rest and during maximal bicycle exercise in eight patients with severe congestive heart failure before and after 8 weeks of therapy with captopril. During therapy, skeletal muscle blood flow at rest increased significantly from 1.5 +/- 0.6 to 2.6 +/- 1.0 ml/100 g per min (p less than 0.05), with a concomitant decrease in the femoral arteriovenous oxygen difference from 10.0 +/- 1.7 to 8.3 +/- 1.9 ml/100 ml (p less than 0.05). Maximal VO2 increased significantly from 13.4 +/- 3.0 to 15.5 +/- 4.1 ml/kg per min (p less than 0.05). In four patients, the increase in maximal VO2 averaged 3.7 ml/kg per min (range 2.7 to 4.9), whereas in the remaining four patients, it was less than 1 ml/kg per min. Overall, peak skeletal muscle blood flow attained during exercise did not change significantly during long-term therapy with captopril (19.6 +/- 6.2 versus 27.6 +/- 14.3 ml/100 g per min, p = NS). However, the four patients with a significant increase in maximal VO2 experienced substantial increases in peak skeletal muscle blood flow and the latter changes were linearly correlated with changes in maximal VO2 (r = 0.95, p less than 0.001). Femoral arteriovenous oxygen difference at peak exercise was unchanged (12.6 +/- 2.6 versus 12.6 +/- 2.4 ml/100 ml). Thus, improvement in maximal VO2 produced by long-term therapy with captopril is associated with an increased peripheral vasodilatory response to exercise, and this improvement only occurs when the peak blood flow is augmented.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  C. Coirault, A. Hagege, D. Chemla, M.-D. Fratacci, C. Guerot, and Y. Lecarpentier Angiotensin-Converting Enzyme Inhibitor Therapy Improves Respiratory Muscle Strength in Patients With Heart Failure Chest, June 1, 2001; 119(6): 1755 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Le Tourneau, P. de Groote, A. Millaire, C. Foucher, C. Savoye, P. Pigny, A. Prat, H. Warembourg, and J. M. Lablanche Effect of mitral valve surgery on exercise capacity, ventricular ejection fraction and neurohormonal activation in patients with severe mitral regurgitation J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2263 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Malendowicz, P. V. Ennezat, M. Testa, L. Murray, E. H. Sonnenblick, T. Evans, and T. H. LeJemtel Angiotensin II Receptor Subtypes in the Skeletal Muscle Vasculature of Patients With Severe Congestive Heart Failure Circulation, October 31, 2000; 102(18): 2210 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Coirault, O. Langeron, F. Lambert, F.-X. Blanc, G. Lerebours, N. Claude, B. Riou, D. Chemla, and Y. Lecarpentier Impaired Skeletal Muscle Performance in the Early Stage of Cardiac Pressure Overload in Rabbits: Beneficial Effects of Angiotensin-Converting Enzyme Inhibition J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 70 - 75. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. Katz, M. Radin, T. Graves, C. Hauck, A. Block, T. H. LeJemtel, and for the Ifetroban Study Group Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril J. Am. Coll. Cardiol., July 1, 1999; 34(1): 170 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yasuda, Y. Goto, H. Sumida, T. Noguchi, T. Baba, S. Miyazaki, and H. Nonogi Angiotensin-Converting Enzyme Inhibition Restores Hepatocyte Growth Factor Production in Patients With Congestive Heart Failure Hypertension, June 1, 1999; 33(6): 1374 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Katz, T. Khan, G. A. Zeballos, L. Mathew, P. Potharlanka, M. Knecht, and J. Whelan Decreased Activity of the L-Arginine–Nitric Oxide Metabolic Pathway in Patients With Congestive Heart Failure Circulation, April 27, 1999; 99(16): 2113 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Demopoulos, M. Yeh, M. Gentilucci, M. Testa, R. Bijou, S. D. Katz, D. Mancini, M. Jones, and T. H. LeJemtel Nonselective ß-Adrenergic Blockade With Carvedilol Does Not Hinder the Benefits of Exercise Training in Patients With Congestive Heart Failure Circulation, April 1, 1997; 95(7): 1764 - 1767. [Abstract] [Full Text]
|
|
|
|
|
|
M. Guazzi, G. Marenzi, M. Alimento, M. Contini, and P. Agostoni Improvement of Alveolar–Capillary Membrane Diffusing Capacity With Enalapril in Chronic Heart Failure and Counteracting Effect of Aspirin Circulation, April 1, 1997; 95(7): 1930 - 1936. [Abstract] [Full Text]
|
|
|
|
|
|
T. S. Rector, A. J. Bank, K. A. Mullen, L. K. Tschumperlin, R. Sih, K. Pillai, and S. H. Kubo Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients With Heart Failure Circulation, June 15, 1996; 93(12): 2135 - 2141. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Mancini, D. Henson, J. L. Manca, L. Donchez, and S. Levine Benefit of Selective Respiratory Muscle Training on Exercise Capacity in Patients With Chronic Congestive Heart Failure Circulation, January 15, 1995; 91(2): 320 - 329. [Abstract] [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
